Search

… Thursday, April 6, 2023 Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging cancer therapies. Their results, published in the Journal of Experimental Medicine on March 6, 2023, identify a targetable mechanism

June’s “MSK Science Spotlight” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute.

… Monday, June 1, 2020 June’s “ MSK Science Spotlight ” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute. Dr. Vale will be presenting

Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).

… Sunday, June 1, 2025 Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial,

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.

… Wednesday, February 18, 2015 In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

… Wednesday, May 16, 2018 VIDEO | 05:17 Lymphoma Update: CAR T Therapies and Checkpoint Inhibitors Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes

A new MSK-led study used single-cell sequencing and other techniques to examine a phenomenon known as “whole-genome doubling” in high-grade serous ovarian carcinoma (HGSOC), the most common and aggressive form of ovarian cancer. The insights could help researchers develop more effective treatment strategies.

… Wednesday, July 16, 2025 Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves — insights that could help researchers develop more effective treatment strategies. While ovarian cancer diagnoses and deaths have decreased over recent decades ,

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Monday, May 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Larry Norton Elected to the American Academy of Arts & Sciences Larry Norton Larry Norton, MD , Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast

Discovery reveals that the genetic causes of cancer may be more complicated than previously thought.

… Wednesday, May 27, 2020 Summary It turns out that finding driver mutations may be more complicated than previously thought: Nearly a quarter of all tumors have two different mutations in the same gene. A major effort in cancer research is the search for driver mutations in tumors. These mutations are

The PICI@MSK fellowship will provide Dr. Delconte with two years of financial support for her research on natural killer cells in cancer.

… Wednesday, March 17, 2021 Rebecca Delconte is a postdoctoral fellow working in the lab of immunologist Joseph Sun in the Sloan Kettering Institute. She is the recipient of the 2021-2022 Parker Institute for Cancer Immunotherapy at MSK  Postdoctoral Fellowship, which will provide two years of financial

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.

… Wednesday, June 18, 2025 Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor,